Drug intelligence / Profile preview

BRKB-300

Development stage: Preclinical
Lead developer: BrickBio
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

BRKB-300 is a preclinical-stage antibody-drug conjugate (ADC) developed by BrickBio. It targets the CD276 antigen (also known as B7-H3), acting as a CD276 inhibitor. The drug is being investigated for the treatment of solid tumors, with its primary therapeutic area being oncology, specifically neoplasms. As an ADC, BRKB-300 combines the specificity of an antibody targeting CD276 with a cytotoxic payload to selectively kill cancer cells expressing this antigen[1].

Targets

B7-H3

Beyond the preview

Go deeper on BRKB-300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BRKB-300.

Explore the full profile